PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells

Blood

Volumn 109, Issue 4, 2007, Pages 1712-1719

  Sharkey, Janelle ^a   Khong, Tiffany ^a   Spencer, Andrew ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BORTEZOMIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIDOSTAURIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN C FOS; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; SN 50; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 33846899418     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-014092     Document Type: Article

References (42)

1. Kyle RA. Diagnosis of multiple myeloma. Semin Oncol. 2002;29:2-4.
2. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther. 1993;59:257-280.
3. Dean NM, McKay R, Condon TP, Bennett CP. Inhibition of protein kinase C-α expression in A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 1994;269:16416-16424.
4. Herbert JM. Protein kinase C: a key factor in the regulation of tumour cell adhesion to the endothelium. Biochem Pharmacol. 1993;45:527-537.
5. Blobe GC, Sachs CW, Khan WA, et al. Selective regulation of expression of protein kinase C (PKC) isoenzyme in multidrug resistant MCF-7 cells: functional significance of enhanced expression of PKC-α. J Biol Chem. 1993;268:658-664.
6. O'Brian CA, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 1989;49:3215-3217.
7. Hirai M, Gamou S, Kobayashi M, Shimizu N. Lung cancer cells often express high levels of protein kinase C activity. Jpn J Cancer Res. 1989;80:204-208.
8. Holen I, Drury NL, Hargreaves PG, Croucher PI. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol. 2001;114:414-421.
9. Thabard W, Collette M, Bataille R, Amiot M. Protein kinase C δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells. Biochem J. 2001;358:193-200.
10. Ikegami Y, Yano S, Nakao K. Antitumour effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol. 1996;70:65-72.
11. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005;24:8259-67.
12. Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N-Benzoylstaurosporine (PKC412) inhibits AkT kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma. 2005;46:899-908.
13. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the Staurosporine derivative CGP 41251. Cancer Res. 1992;52:5353-5358.
14. Chen J, DeAngelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101:14479-14484.
15. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol. 1996;16:4504-4511.
16. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999;21:326-329.
17. Tanos T, Marinissen MJ, Leskow FC, et al. Phosphorylation of c-fos by members of the p38 MAPK family: role in the AP-1 response to UV light. J Biol Chem. 2005;280:18842-18852.
18. Edwards J, Krishna NS, Mukherjee R, Bartlett MS. The role of c-jun and c-fos expression in androgen-independent prostate cancer. J Pathol. 2004;204:153-158.
19. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270:16483-16486.
20. Yang Y, Ikezoe S, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci. 2004;95:176-180.
21. Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996;380:75-79.
22. Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005;24:6516-6524.
23. Beebe SJ, Holloway R, Rannels SR, Corbin JD. Two classes of cAMP analogs which are selective for the two different cAMP-binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes. J Biol Chem. 1984;259:3539-3547.
24. Tagliaferri P, Katsaros D, Clair T, Neckers L, Robins RK, Cho-Chung YS. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J Biol Chem. 1988;263:409-416.
25. Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through reactive oxygen species and Akt-dependent process. Oncogene. 2005;24:3797-3809.
26. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPLs in head and neck squamous carcinoma cells. Oncogene. 2006;25:2785-2794.
27. + cells sensitive and resistant to ST1571. Blood. 2003;102:3765-3774.
28. Dent P, Yacoub A, Contessa J, et al. Stress and radiation-induced activation of multiple intracelleular pathways. Rad Res. 2003;158:283-300.
29. George P, Bali P, Cohen P, et al. Cotreatment with 17-allyamino- demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukaemia cells with mutant FLT-3. Cancer Res. 2004;64:3645-3652.
30. Monnerat C, Henriksson R, Le Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), an oral inhibitor of protein kinase C, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol. 2004;15:316-323.
31. Eder JP, Garcia-Carbonero R, Clark JW, et al. A phase I trial of daily oral 4′-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Investigational New Drugs. 2004;22;139-150.
32. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumour progression in multiple myeloma. Blood. 2001;97:729-736.
33. Kang H-J, Soh Y, Kim M-S, et al. Roles of JNK-1 and p38 in selective induction of apoptosis by capsaicin in ras-transformed human breast epithelial cells. Int J Cancer. 2003;103:475-482.
34. 2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Cancer Res. 2000;60:400-408.
35. Wang T-H, Wang H-S, Ichijo H, et al. Microtubule-interfering agents activate c-jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 1998;273:4928-4936.
36. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH. The role of c-jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. J Biol Chem. 1996;271:31929-31936.
37. Gauthier-Rouviere C, Fernandez A, Lamb NJC. ras-induced c-fos expression and proliferation in living rat fibroblasts involves the C-kinase activation and the serum response element pathway. EMBO J. 1990;9:171-180.
38. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 2001;21:6913-6926.
39. Schutze S, Machleidt T, Kronke M. Mechanisms of tumor necrosis factor action. Semin Oncol. 1992;19:16-24.
40. Mitsiades NS, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
41. Fahy B, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res. 2003;113:88-95.
42. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107:1092-1100.